# A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma

> **NCT00426764** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 131 (actual)

## Conditions studied

- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** Romidepsin

## Key facts

- **NCT ID:** NCT00426764
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06-19
- **Primary completion:** 2010-11-11
- **Final completion:** 2018-05-17
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2020-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00426764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00426764, "A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00426764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*